葛兰重金出手！朱少醒、范妍也参与了！

Group 1 - The article highlights significant investments by prominent fund managers in the innovative drug company Bai Li Tian Heng during a recent market adjustment in the pharmaceutical sector [3][11][15] - Fund manager Ge Lan's two funds invested a total of 6.79 billion yuan in Bai Li Tian Heng's private placement, indicating strong confidence in the company's growth potential [3][11] - The funds managed by Ge Lan have been increasing their holdings in Bai Li Tian Heng over the past year, with the total shares held rising to 427.97 million by the second quarter of this year [6][9] Group 2 - Bai Li Tian Heng's recent private placement raised 3.764 billion yuan by issuing 11.8738 million shares at a price of 317 yuan each, with several well-known fund managers participating [11][12] - The funds involved in the placement include those managed by Zhu Shaoxing and Fan Yan, among others, reflecting a broader institutional interest in the innovative drug sector [11][15] - The innovative drug sector continues to attract significant capital inflows, with various ETFs seeing substantial net subscriptions despite recent market adjustments [15][16] Group 3 - The article discusses the long-term growth potential of China's innovative drug industry, which is expected to experience explosive growth in the global market [16] - China's drug development capabilities are gaining international recognition, with the country ranking second globally in the number of drugs under development [16] - Recent policy changes are creating a favorable environment for the innovative drug sector, despite short-term volatility [16]